Cross-diagnostic analysis of cognitive control in mental illness: Insights from the CNTRACS consortium.


Journal

Schizophrenia research
ISSN: 1573-2509
Titre abrégé: Schizophr Res
Pays: Netherlands
ID NLM: 8804207

Informations de publication

Date de publication:
06 2019
Historique:
received: 26 02 2018
revised: 17 12 2018
accepted: 17 01 2019
pubmed: 2 2 2019
medline: 18 8 2020
entrez: 2 2 2019
Statut: ppublish

Résumé

In recent years, psychiatry research has increasingly focused on understanding mental illnesses from a cross-diagnostic, dimensional perspective in order to better align their neurocognitive features with underlying neurobiological mechanisms. In this multi-site study, we examined two measures of cognitive control (d-prime context and lapsing rate) during the Dot Probe Expectancy (DPX) version of the AX-Continuous Performance Task in patients with either schizophrenia (SZ), schizoaffective disorder (SZ-A), or Type I bipolar disorder (BD) as well as healthy control (HC) subjects. We hypothesized significantly lower d-prime context and higher lapsing rate in SZ and SZ-A patients and intermediate levels in BD patients relative to HC. 72 HC, 84 SZ, 77 SZ-A, and 58 BD patients (ages 18-56) were included in the final study sample. Significant main effects of diagnosis were observed on d-prime context (F(3,279) = 9.59, p < 0.001) and lapsing (F(3,279) = 8.08, p < 0.001). A priori linear contrasts suggesting intermediate dysfunction in BD patients were significant (p < 0.001), although post-hoc tests showed the BD group was only significantly different from HC on d-prime context. Group results for d-prime context remained significant after covarying for lapsing rate. Primary behavioral measures were associated with mania and disorganization symptoms as well as everyday functioning. These findings suggest a continuum of dysfunction in cognitive control (particularly d-prime context) across diagnostic categories in psychiatric illness. These results further suggest that lapsing and d-prime context, while related, make unique contributions towards explaining deficits in cognitive control in these disorders.

Sections du résumé

BACKGROUND
In recent years, psychiatry research has increasingly focused on understanding mental illnesses from a cross-diagnostic, dimensional perspective in order to better align their neurocognitive features with underlying neurobiological mechanisms. In this multi-site study, we examined two measures of cognitive control (d-prime context and lapsing rate) during the Dot Probe Expectancy (DPX) version of the AX-Continuous Performance Task in patients with either schizophrenia (SZ), schizoaffective disorder (SZ-A), or Type I bipolar disorder (BD) as well as healthy control (HC) subjects. We hypothesized significantly lower d-prime context and higher lapsing rate in SZ and SZ-A patients and intermediate levels in BD patients relative to HC.
METHODS
72 HC, 84 SZ, 77 SZ-A, and 58 BD patients (ages 18-56) were included in the final study sample.
RESULTS
Significant main effects of diagnosis were observed on d-prime context (F(3,279) = 9.59, p < 0.001) and lapsing (F(3,279) = 8.08, p < 0.001). A priori linear contrasts suggesting intermediate dysfunction in BD patients were significant (p < 0.001), although post-hoc tests showed the BD group was only significantly different from HC on d-prime context. Group results for d-prime context remained significant after covarying for lapsing rate. Primary behavioral measures were associated with mania and disorganization symptoms as well as everyday functioning.
CONCLUSIONS
These findings suggest a continuum of dysfunction in cognitive control (particularly d-prime context) across diagnostic categories in psychiatric illness. These results further suggest that lapsing and d-prime context, while related, make unique contributions towards explaining deficits in cognitive control in these disorders.

Identifiants

pubmed: 30704863
pii: S0920-9964(19)30016-7
doi: 10.1016/j.schres.2019.01.018
pmc: PMC6544491
mid: NIHMS1519991
pii:
doi:

Types de publication

Comparative Study Journal Article Research Support, N.I.H., Extramural

Langues

eng

Sous-ensembles de citation

IM

Pagination

377-383

Subventions

Organisme : NIMH NIH HHS
ID : R01 MH084826
Pays : United States
Organisme : NIMH NIH HHS
ID : R01 MH084821
Pays : United States
Organisme : NIMH NIH HHS
ID : R01 MH084861
Pays : United States
Organisme : NIMH NIH HHS
ID : R01 MH059883
Pays : United States
Organisme : NIMH NIH HHS
ID : R01 MH084840
Pays : United States
Organisme : NIMH NIH HHS
ID : F32 MH114325
Pays : United States

Informations de copyright

Copyright © 2019 Elsevier B.V. All rights reserved.

Références

Neuropsychopharmacology. 2011 Jan;36(1):316-38
pubmed: 20844478
Neuropsychopharmacology. 2018 Feb;43(3):598-606
pubmed: 28948978
Am J Psychiatry. 2010 Jul;167(7):748-51
pubmed: 20595427
Bipolar Disord. 2007 May;9(3):230-7
pubmed: 17430297
Schizophr Bull. 2007 Nov;33(6):1364-72
pubmed: 17341468
Schizophr Bull. 2013 Mar;39(2):257-62
pubmed: 23236079
Mem Cognit. 2008 Sep;36(6):1144-50
pubmed: 18927032
Neuropsychologia. 2017 Feb;96:262-273
pubmed: 28126626
Front Hum Neurosci. 2015 Oct 06;9:502
pubmed: 26500517
J Abnorm Psychol. 1999 Feb;108(1):120-33
pubmed: 10066998
Schizophr Bull. 1997;23(1):51-61
pubmed: 9050112
J Cogn Neurosci. 2015 Dec;27(12):2309-23
pubmed: 26401815
Psychon Bull Rev. 2007 Jun;14(3):527-33
pubmed: 17874601
Psychophysiology. 2018 Mar;55(3):
pubmed: 28295391
Psychon Bull Rev. 2007 Apr;14(2):230-6
pubmed: 17694906
Nat Neurosci. 2006 Jul;9(7):971-8
pubmed: 16767087
JAMA Psychiatry. 2015 Mar;72(3):226-34
pubmed: 25588194
J Clin Psychiatry. 2003 Jun;64(6):663-7
pubmed: 12823080
Neuropsychologia. 2016 May;85:310-26
pubmed: 26951932
Schizophr Bull. 2012 Jan;38(1):34-42
pubmed: 22114099
Br J Psychiatry. 1978 Nov;133:429-35
pubmed: 728692
Neuroimage Clin. 2013 Apr 22;2:590-9
pubmed: 24179809
Neuron. 2011 Feb 24;69(4):680-94
pubmed: 21338879
Psychon Bull Rev. 2018 Apr;25(2):754-760
pubmed: 28577275
Neuroimage. 2015 May 1;111:611-21
pubmed: 25725466
Neurosci Biobehav Rev. 2016 Feb;61:66-89
pubmed: 26691725
Schizophr Res. 2011 Dec;133(1-3):250-4
pubmed: 21996268
Am J Psychiatry. 1997 Apr;154(4 Suppl):1-63
pubmed: 9090368
Neuroimage. 2007 Nov 15;38(3):640-8
pubmed: 17884586
Schizophr Bull. 2012 Jan;38(1):104-13
pubmed: 22199092
J Abnorm Psychol. 2018 Nov;127(8):781-788
pubmed: 29781657
Psychol Med. 2013 Dec;43(12):2535-45
pubmed: 23522057
Neurosci Biobehav Rev. 2016 Aug;67:57-78
pubmed: 26743859
Psychol Assess. 2010 Mar;22(1):131-41
pubmed: 20230159
Psychiatry Res. 2015 Feb 28;225(3):254-62
pubmed: 25601802
Am J Psychiatry. 2008 Aug;165(8):1006-14
pubmed: 18519527
Cogn Affect Behav Neurosci. 2012 Jun;12(2):241-68
pubmed: 22282036
Proc Natl Acad Sci U S A. 2009 May 5;106(18):7351-6
pubmed: 19380750
Neuroscientist. 2014 Dec;20(6):652-64
pubmed: 24622818
Psychol Med. 2016 May;46(7):1497-507
pubmed: 26899136
J Abnorm Psychol. 2003 Feb;112(1):132-43
pubmed: 12653421
Schizophr Bull. 2012 Jan;38(1):135-43
pubmed: 22101963

Auteurs

Jason Smucny (J)

Department of Psychiatry and Behavioral Sciences, University of California, Davis, Davis, USA. Electronic address: jsmucny@ucdavis.edu.

Deanna M Barch (DM)

Department of Psychology, Washington University in St. Louis, St. Louis, USA.

James M Gold (JM)

Maryland Psychiatric Research Center, Catonsville, USA.

Milton E Strauss (ME)

Department of Psychology, University of New Mexico, Albuquerque, NM, USA.

Angus W MacDonald (AW)

University of Minnesota, Minneapolis, USA.

Megan A Boudewyn (MA)

Department of Psychiatry and Behavioral Sciences, University of California, Davis, Davis, USA.

J Daniel Ragland (JD)

Department of Psychiatry and Behavioral Sciences, University of California, Davis, Davis, USA.

Steven M Silverstein (SM)

Rutgers - The State University of New Jersey, New Brunswick, USA.

Cameron S Carter (CS)

Department of Psychiatry and Behavioral Sciences, University of California, Davis, Davis, USA.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH